RGX-314
Wet Age-related Macular Degeneration (wAMD)
Key Facts
About REGENXBIO
REGENXBIO is a publicly traded gene therapy leader built around its foundational NAV Technology Platform, comprising exclusive rights to over 100 novel AAV vectors, including the high-performing AAV8 and AAV9. The company's strategy combines advancing its own clinical pipeline, most notably in wet AMD with RGX-314, with a lucrative licensing model that includes partnerships with major biopharma companies like Novartis, Pfizer, and Takeda. With multiple clinical readouts expected in the near term and a strong financial position, REGENXBIO is positioned to be a key player in the next generation of gene therapies.
View full company profileAbout REGENXBIO
REGENXBIO is a publicly traded gene therapy leader built around its foundational NAV Technology Platform, comprising exclusive rights to over 100 novel AAV vectors, including the high-performing AAV8 and AAV9. The company's strategy combines advancing its own clinical pipeline, most notably in wet AMD with RGX-314, with a lucrative licensing model that includes partnerships with major biopharma companies like Novartis, Pfizer, and Takeda. With multiple clinical readouts expected in the near term and a strong financial position, REGENXBIO is positioned to be a key player in the next generation of gene therapies.
View full company profileOther Wet Age-related Macular Degeneration (wAMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Tarcocimab Tedromer (KSI-301) | Kodiak Sciences | Phase 2b/3 & Phase 3 |
| UBX1325 (foselutoclax) | Unity Biotechnology | Phase 2 |